Skip to main content

Table 5 Rocket-AF study: primary ischemic outcomes

From: Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective

Outcomes Rivaroxaban Warfarin P NNT
Primary outcomes (noninferiority)a 1.71 2.16 <0.001 222
Primary outcomes (on treatment) 1.70 2.15 0.015 222
Non-central nervous system embolism 0.04 0.19 0.003 667
Vascular death, stroke, embolism 3.11 3.63 0.034 192
Ischemic stroke 1.34 1.42 0.581 1250
Unknown cause 0.06 0.10 0.366 2500
  1. NNT, number needed to treat. Data from Mahaffey KW. AHA Scientific Sessions 2010.
  2. aStroke and extracranial embolism, event rate per 100 patients/year.